Abstract
Stem cell and gene therapy approaches have held out much hope for the development of new tools to treat disease. Therapeutic approaches based on these methods have only rarely found their way into the clinic. The linking of stem cell therapy with selective gene therapy enhances therapeutic options for the regeneration or replacement of diseased or missing cells. This review focuses on the rationale and preliminary results of combining stem cell and gene therapy. Special emphasis is placed on various molecular techniques currently used to genetically engineer stem cells. Viral and nonviral genes delivering technologies are detailed as are techniques for the modulation of gene expression in the context of stem cell recruitment and differentiation. Finally potential clinical applications for this new therapeutic strategy are discussed.
Keywords: Cell Therapy, progenitor cells, tissue engineering, gene delivery, stem cell recruitment, cell differentiation, angiogenesis, tumor stem cell
Current Gene Therapy
Title: Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Volume: 7 Issue: 4
Author(s): Claudius Conrad, Rashmi Gupta, Hema Mohan, Hanno Niess, Christiane J. Bruns, Reinhard Kopp, Irene von Luettichau, Markus Guba, Christopher Heeschen, Karl-Walter Jauch, Ralf Huss and Peter J.Nelson
Affiliation:
Keywords: Cell Therapy, progenitor cells, tissue engineering, gene delivery, stem cell recruitment, cell differentiation, angiogenesis, tumor stem cell
Abstract: Stem cell and gene therapy approaches have held out much hope for the development of new tools to treat disease. Therapeutic approaches based on these methods have only rarely found their way into the clinic. The linking of stem cell therapy with selective gene therapy enhances therapeutic options for the regeneration or replacement of diseased or missing cells. This review focuses on the rationale and preliminary results of combining stem cell and gene therapy. Special emphasis is placed on various molecular techniques currently used to genetically engineer stem cells. Viral and nonviral genes delivering technologies are detailed as are techniques for the modulation of gene expression in the context of stem cell recruitment and differentiation. Finally potential clinical applications for this new therapeutic strategy are discussed.
Export Options
About this article
Cite this article as:
Claudius Conrad , Rashmi Gupta , Hema Mohan , Hanno Niess , Christiane J. Bruns , Reinhard Kopp , Irene von Luettichau , Markus Guba , Christopher Heeschen , Karl-Walter Jauch , Ralf Huss and Peter J.Nelson , Genetically Engineered Stem Cells for Therapeutic Gene Delivery, Current Gene Therapy 2007; 7 (4) . https://dx.doi.org/10.2174/156652307781369119
DOI https://dx.doi.org/10.2174/156652307781369119 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells In Vitro
Anti-Cancer Agents in Medicinal Chemistry Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets